|
|
Strategic Navigators
Ulcerative Colitis Clinical Pipeline Analysis
Pages: 106
Published: August 2022
Individual License: $4,950
Team License: $5,950
The ulcerative colitis clinical pipeline has many exciting compounds in development. US gastroenterologists’ enthusiasm for these upcoming launches ranges from highly excited to unmoved.
Ulcerative Colitis Clinical Pipeline Analysis uncovers HCPs’ perspectives on UC treatments in development, including JAK inhibitors, such as Upadacitinib and Filgotinib, S1Ps, such as Etrasimod, and IL-23 inhibitors, such as Mirikizumab and Guselkumab. Additionally, the report’s data also include gastroenterologists’ expectations for each pipeline treatment, as well as areas where they believe these new therapies will compete best against existing UC brands.
This report shares key insights from US gastroenterologists about the ulcerative colitis pipeline. Lastly, the report details the expected impact of each UC pipeline drug to the ulcerative colitis market, how they will compete against existing products and which clinical attributes are advantageous for each compound.
Overview of the Ulcerative Colitis Clinical Pipeline
The ulcerative colitis market is poised for a host of new market entrants. Ulcerative Colitis Clinical Pipeline Analysis examines each UC pipeline drug’s strengths and weaknesses across six key clinical attributes:
- Access
- Dosing
- Efficacy
- Safety
- Support
- Tolerability
Furthermore, the report also conveys US gastroenterologists’ familiarity and excitement about the ulcerative colitis pipeline.
Pipeline Treatments Analyzed
- Brazikumab
- Cobitolimod
- Etrasimod
- Filgotinib
- Guselkumab
- Mirikizumab
- Risankizumab
- Upadacitinib
Strategic Questions Answered about the Ulcerative Colitis Clinical Pipeline
- Awareness: What is the level of awareness and excitement among gastroenterologists for each of the leading UC pipeline drugs?
- Perceptions: How do gastroenterologists perceive pipeline therapies in terms of their efficacy, safety, dosing, tolerability, access, and support?
- Competitive Impact: Which inline UC brands will be most impacted in the future by drugs in the ulcerative colitis pipeline?
Summary of Strategic Ulcerative Colitis Clinical Pipeline
- Gastroenterologists are more familiar with Upadacitinib than any other UC pipeline drug. Consequently, they expect it to have better efficacy, safety, dosing and tolerability than competitor ulcerative colitis treatments.
- With expectations for better efficacy, safety and tolerability, gastroenterologists believe Etrasimod will have a significant impact when it launches. Compared to other UC pipeline drugs, however, Etrasimod’s access may be an issue
- US HCPs expect Filgotinib’s dosing to be better than all other drugs in the ulcerative colitis pipeline. Gastroenterologists expect Filgotinib to compete well against JAK inhibitor, such as Xeljanz.
Benefits of Purchasing Ulcerative Colitis Clinical Pipeline
- Cost-efficient insights about the ulcerative colitis pipeline to support your strategic decisions.
- Insights drawn from in-depth interviews among global KOLs and surveys of more than 125 gastroenterologists
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s ulcerative colitis strategist for 1-year.
Table of Contents
Executive Summary – 5
- The Strategic Six – Key Insights about Ulcerative Colitis Clinical Pipeline – 6
- Impact Scores for Ulcerative Colitis Clinical Pipeline Products- 7
- Ulcerative Colitis Clinical Pipeline Expectations vs. Competitors – 8
- UC Clinical Pipeline Superlatives – 9
Ulcerative Colitis Clinical Pipeline Awareness & Excitement – 10
- Pipeline Treatments with the Highest Familiarity – 11
- Pipeline Treatments HCPs Have Heard of But Are Not Familiar With – 12
- Pipeline Treatments with the Least Familiarity 13
- Pipeline Treatments with the Highest Excitement -14
- Pipeline Treatments with the Highest Ambivalence – 15
- Pipeline Treatment Competitive Outlook – 16
Upadacitinib Competitive Outlook – 17
- Upadacitinib Competitive Summary – 18
- Upadacitinib Familiarity – 19
- Upadacitinib Excitement – 20
- Upadacitinib Competitors – 21
- Upadacitinib Efficacy Expectations vs. Competitors – 22
- Upadacitinib Safety Expectations vs. Competitors – 23
- Upadacitinib Dosing Expectations vs. Competitors – 24
- Upadacitinib Tolerability Expectations vs. Competitors – 25
- Upadacitinib Access Expectations vs. Competitors – 26
- Upadacitinib Support Expectations vs. Competitors – 27
Etrasimod Competitive Outlook – 28
- Etrasimod Competitive Summary – 29
- Etrasimod Familiarity – 30
- Etrasimod Excitement – 31
- Etrasimod Competitors – 32
- Etrasimod Efficacy Expectations vs. Competitors – 33
- Etrasimod Safety Expectations vs. Competitors – 34
- Etrasimod Dosing Expectations vs. Competitors – 35
- Etrasimod Tolerability Expectations vs. Competitors – 36
- Etrasimod Access Expectations vs. Competitors – 37
- Etrasimod Support Expectations vs. Competitors – 38
Filgotinib Competitive Outlook – 39
- Filgotinib Competitive Summary – 40
- Filgotinib Familiarity – 41
- Filgotinib Excitement – 42
- Filgotinib Competitors – 43
- Filgotinib Efficacy Expectations – 44
- Filgotinib Safety Expectations – 45
- Filgotinib Dosing Expectations – 46
- Filgotinib Tolerability Expectations – 47
- Filgotinib Access Expectations – 48
- Filgotinib Support Expectations – 49
Risankizumab Competitive Outlook – 50
- Risankizumab Competitive Summary – 51
- Risankizumab Familiarity – 52
- Risankizumab Excitement – 53
- Risankizumab Competitors – 54
- Risankizumab Efficacy Expectations vs. Competitors – 55
- Risankizumab Safety Expectations vs. Competitors – 56
- Risankizumab Dosing Expectations vs. Competitors – 57
- Risankizumab Tolerability Expectations vs. Competitors -58
- Risankizumab Access Expectations vs. Competitors – 59
- Risankizumab Support Expectations vs. Competitors – 60
Mirikizumab Competitive Outlook – 61
- Mirikizumab Competitive Summary – 62
- Mirikizumab Familiarity – 63
- Mirikizumab Excitement – 64
- Mirikizumab Competitors – 65
- Mirikizumab Efficacy Expectations – 66
- Mirikizumab Safety Expectations – 67
- Mirikizumab Dosing Expectations – 68
- Mirikizumab Tolerability Expectations – 69
- Mirikizumab Access Expectations – 70
- Mirikizumab Support Expectations – 71
Guselkumab Competitive Outlook – 72
- Guselkumab Competitive Summary – 73
- Guselkumab Familiarity – 74
- Guselkumab Excitement – 75
- Guselkumab Competitors – 76
- Guselkumab Efficacy Expectations – 77
- Guselkumab Safety Expectations – 78
- Guselkumab Dosing Expectations – 79
- Guselkumab Tolerability Expectations – 80
- Guselkumab Access Expectations – 81
- Guselkumab Support Expectations – 82
Brazikumab Competitive Outlook – 83
- Brazikumab Competitive Summary – 84
- Brazikumab Familiarity – 85
- Brazikumab Excitement – 86
- Brazikumab Competitors – 87
- Brazikumab Efficacy Expectations – 88
- Brazikumab Safety Expectations – 89
- Brazikumab Dosing Expectations – 90
- Brazikumab Tolerability Expectations – 91
- Brazikumab Access Expectations – 92
- Brazikumab Support Expectations – 93
Cobitolimod Competitive Outlook – 94
- Cobitolimod Competitive Summary – 95
- Cobitolimod Familiarity – 96
- Cobitolimod Excitement – 97
- Cobitolimod Competitors – 98
- Cobitolimod Efficacy Expectations – 99
- Cobitolimod Safety Expectations – 100
- Cobitolimod Dosing Expectations – 101
- Cobitolimod Tolerability Expectations – 102
- Cobitolimod Access Expectations – 103
- Cobitolimod Support Expectations – 104
